CA2457385A1 - Preparation enterique de fluoxetine - Google Patents

Preparation enterique de fluoxetine Download PDF

Info

Publication number
CA2457385A1
CA2457385A1 CA002457385A CA2457385A CA2457385A1 CA 2457385 A1 CA2457385 A1 CA 2457385A1 CA 002457385 A CA002457385 A CA 002457385A CA 2457385 A CA2457385 A CA 2457385A CA 2457385 A1 CA2457385 A1 CA 2457385A1
Authority
CA
Canada
Prior art keywords
fluoxetin
enteric
formulation
group
layer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002457385A
Other languages
English (en)
Inventor
Abhijit Mukund Deshmukh
Ujwal Damu Kolhe
Vipin Tatyasaheb Dhanorkar
Mailatur Sivaraman Mohan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dr Reddys Laboratories Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2457385A1 publication Critical patent/CA2457385A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne une préparation entérique de fluoxétine avantageuse sur le plan industriel n'impliquant pas l'utilisation de saccharose et de succinate d'acétate d'hydroxypropylméthylcellulose. Cette invention a également trait à des préparations entériques de fluoxétine sous forme de comprimés ou de gélules pourvues d'une couche de séparation facultative. Lorsque ces préparations se présentent sous forme de gélules, la couche de séparation est la coque de la gélule même, ce qui permet de réduire l'étape de traitement desdites préparations entériques. La préparation de cette invention, ainsi que la fluoxétine ou ses sels acceptables pharmaceutiquement, les solvates, les enantiomères ou les mélanges correspondants contenant un mélange racémique sont également considérés comme étant dans la portée de cette invention.
CA002457385A 2001-08-06 2002-04-19 Preparation enterique de fluoxetine Abandoned CA2457385A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN647/MAS/2001 2001-08-06
IN647MU2001 2001-08-06
PCT/IB2002/001268 WO2003013480A1 (fr) 2001-08-06 2002-04-19 Preparation enterique de fluoxetine

Publications (1)

Publication Number Publication Date
CA2457385A1 true CA2457385A1 (fr) 2003-02-20

Family

ID=11097262

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002457385A Abandoned CA2457385A1 (fr) 2001-08-06 2002-04-19 Preparation enterique de fluoxetine

Country Status (2)

Country Link
CA (1) CA2457385A1 (fr)
WO (1) WO2003013480A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004058228A1 (fr) * 2002-12-24 2004-07-15 Lupin Limited Composition de fluoxetine a enrobage enterique
PT1502587E (pt) * 2003-07-30 2007-01-31 Pharmathen Sa Formulação de libertação prolongada para cloridrato de venlafaxina
WO2009006299A2 (fr) * 2007-06-29 2009-01-08 Dr. Reddy's Laboratories Ltd. Systèmes à multiples particules
ES2793530T3 (es) * 2014-05-19 2020-11-16 Tillotts Pharma Ag Cápsulas revestidas de liberación modificada
EP2946773A1 (fr) 2014-05-19 2015-11-25 Tillotts Pharma AG Capsules enrobées à libération modifiée

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4314081A (en) 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
US4626549A (en) 1974-01-10 1986-12-02 Eli Lilly And Company Treatment of obesity with aryloxyphenylpropylamines
US5104899A (en) 1990-08-13 1992-04-14 Sepracor, Inc. Methods and compositions for treating depression using optically pure fluoxetine
US5708035A (en) 1991-02-04 1998-01-13 Sepracor Inc. Methods of use and compositions of R(-) fluoxetine
US5889186A (en) 1994-12-16 1999-03-30 Uop Process for preparation of the pharmaceutically desired (S)-oxetine enantiomers
GB9514842D0 (en) * 1995-07-20 1995-09-20 Smithkline Beecham Plc Novel formulation
DE19651040C2 (de) 1996-12-09 1999-01-28 Bayer Ag Verfahren zur Herstellung von 2-Amino-5-alkyl-phenolen
US5910319A (en) 1997-05-29 1999-06-08 Eli Lilly And Company Fluoxetine enteric pellets and methods for their preparation and use
UA63953C2 (uk) * 1997-07-01 2004-02-16 Пфайзер Продактс Інк. Дозована форма уповільненого вивільнення, що містить сертралін, (варіанти) та спосіб лікування (варіанти)

Also Published As

Publication number Publication date
WO2003013480A1 (fr) 2003-02-20

Similar Documents

Publication Publication Date Title
US8557282B2 (en) Extended release compositions comprising as active compound venlafaxine hydrochloride
US6958161B2 (en) Modified release coated drug preparation
US6515010B1 (en) Carvedilol methanesulfonate
AU2002349001C1 (en) Pharmaceutical containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol and providing delayed release of the active ingredient
US7550153B2 (en) Pantoprazole multiparticulate formulations
US20090175935A1 (en) Pharmaceutical compositions of duloxetine
US20040043996A1 (en) Controlled release formulation of lamotrigine
US20080226711A1 (en) Pharmaceutical compositions of duloxetine
US20080206335A1 (en) Multiparticulate controlled release selective serotonin reuptake inhibitor formulations
EP2533766B1 (fr) Mini-comprimés pharmaceutiques à libération prolongée d'acétate de flécaïnide
CA2374039C (fr) Preparations d'inhibiteurs specifiques du recaptage de la serotonine a liberation multiparticulaire regulee
US20090220593A1 (en) Extended release dosage forms of quetiapine
EP1392252B1 (fr) Composition pharmaceutique contenant du poloxamer comme un laxatif emollient et des particules de bisacodyl a enrobage enterique
CA2457385A1 (fr) Preparation enterique de fluoxetine
US20080118554A1 (en) Pharmaceutical compositions comprising a combination of piperidinoalkanol and decongestant
CA2480783C (fr) Preparation a liberation modifiee amelioree
US20040170688A1 (en) Enteric formulation of fluoxetin
EP3290023B1 (fr) Composition pharmaceutique à libération prolongée contenant de la rivastigmine
US20090175934A1 (en) Extended Release Pharmaceutical Formulation of Venlafaxine and Method of Manufacturing the Same
US20090130206A1 (en) Controlled Release Compositions of an Antidepressant Agent
CA2739611A1 (fr) Medicament contenant du 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol, caracterise par une liberation differee du principe actif

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued